Browse the evidence

Skeletal muscle disuse (immobilization, bed rest, or unloading) causes rapid muscle atrophy primarily through a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged or is not the primary driver.

If you are immobilized or unable to exercise (e.g., cast, bed rest), your muscles will stop building protein rapidly, leading to atrophy. You cannot simply 'wait it out' without loss. Focus on countermeasures like high-quality protein intake and any permitted mechanical loading (like electrical stimulation or isometric exercises) to mitigate the drop in muscle protein synthesis.

Obesity causes male infertility through multiple mechanisms including hormonal disruption (low testosterone/high estrogen), increased scrotal temperature, and oxidative stress from adipokines.

If you are obese and struggling with fertility, weight loss is a primary medical treatment. It can restore hormonal balance and improve semen quality. Consult a doctor for a weight management plan.

In obese individuals, systemic inflammation drives a shift in tryptophan metabolism toward the kynurenine pathway (increased KYN/TRP ratio) and away from serotonin and microbial indole production, correlating with higher inflammatory markers.

This research highlights that obesity is linked to specific changes in how your body processes tryptophan, shifting it away from serotonin production and toward inflammatory pathways. While this paper does not offer a direct intervention, it suggests that managing systemic inflammation and gut health (via diet and lifestyle) may be key to normalizing these metabolic pathways.

Mitochondrial dysfunction during aging leads to the release of mitochondrial DAMPs (specifically cell-free mtDNA and TFAM), which trigger sterile inflammation via TLR, NLRP3, and cGAS-STING pathways, thereby driving 'inflamm-aging'.

Focus on maintaining mitochondrial health through regular physical activity, particularly resistance and endurance training, which supports mitochondrial biogenesis and quality control. This helps reduce the release of inflammatory mitochondrial DNA fragments into the bloodstream, potentially lowering chronic age-related inflammation.

DNA methylation patterns change dynamically throughout the lifespan, serving as a molecular marker for monitoring aging and predicting life expectancy, although the underlying causal mechanisms remain largely undiscovered.

Your DNA methylation patterns are not fixed; they change with age and environment. While we cannot yet reverse aging via methylation, tracking these changes (biological age) may offer insights into health status. Lifestyle factors like physical activity and diet influence these patterns, suggesting that maintaining a healthy lifestyle may positively impact your epigenetic profile.

Long-term glucocorticoid treatment causes insulin resistance, glucose intolerance, and abnormal weight gain by suppressing osteoblast function and osteocalcin synthesis; disrupting this skeletal signaling pathway prevents these metabolic adverse effects.

This research suggests that the metabolic side effects of long-term glucocorticoid use (like weight gain and insulin resistance) are partly driven by the suppression of bone-derived hormones (osteocalcin). While this is a mouse study, it implies that maintaining bone health or osteocalcin levels might mitigate metabolic risks in patients on steroids, though direct human interventions are not yet established.

Short-term ADT (3-6 months) induces insulin resistance and hyperinsulinemia while maintaining normal fasting glucose levels, whereas long-term ADT (12+ months) leads to frank hyperglycemia and diabetes.

Monitor your blood sugar closely. In the first few months of treatment, your body may compensate for insulin resistance by producing more insulin, keeping blood sugar normal. However, after a year, this compensation often fails, leading to diabetes. Regular glucose tolerance tests are recommended for those on long-term therapy.

ADT causes unfavorable body composition changes, specifically increasing fat mass (particularly visceral/subcutaneous) and decreasing lean body mass, which correlates with rising insulin levels.

Expect to gain fat and lose muscle on ADT. This is not just cosmetic; the fat gain, especially around the abdomen, drives insulin resistance. Focus on resistance training and protein intake to mitigate muscle loss, and cardiovascular exercise to manage fat gain.

Surgical treatment (intestinal bypass or gastric restriction) produces significant, sustained weight loss and remission of obesity-related comorbidities (hypertension, diabetes, pulmonary issues) in severely obese patients, whereas conservative treatments are largely ineffective.

For individuals with severe (morbid) obesity who have not succeeded with diet and lifestyle changes, surgical options like intestinal bypass or gastric restriction are the most effective treatments for achieving significant, long-term weight loss and resolving related health issues like diabetes and hypertension. While surgery carries risks, modern gastric restriction techniques have fewer complications than older bypass methods, and the psychological and social benefits (improved body image, relationships, and employment) are substantial.

Genetic deficiency of the liver-expressed protein Cideb confers resistance to high-fat diet-induced obesity and liver steatosis by enhancing fatty acid oxidation and suppressing lipogenesis.

This research identifies Cideb as a critical regulator in the liver. While you cannot directly 'take' Cideb, the findings suggest that therapies targeting this protein or its downstream effects (increasing fatty acid oxidation and decreasing lipogenesis) could treat obesity and fatty liver. For now, the key takeaway is that enhancing fatty acid oxidation and reducing de novo lipogenesis are effective strategies for managing diet-induced obesity.

Cideb deficiency reduces hepatic lipogenesis by downregulating SREBP1c and its downstream targets (ACC, FAS, SCD1), while simultaneously increasing fatty acid oxidation.

This study identifies Cideb as a key regulator of liver fat balance. By reducing Cideb activity, the liver shifts from storing fat (lipogenesis) to burning it (oxidation). This suggests that therapies targeting Cideb or its regulators (like SREBP1c) could be effective in treating fatty liver disease and obesity by rebalancing these metabolic pathways.

Growth hormone does not accelerate fat loss in obese subjects during caloric restriction, despite increasing free fatty acid (FFA) mobilization.

Do not use Growth Hormone expecting it to help you lose more fat. It increases the amount of fat in your blood temporarily, but it does not help you lose more body fat than dieting alone. It is not an effective fat-loss strategy.

Growth hormone causes fluid retention (edema) and weight gain in the first week of treatment, which resolves after treatment stops, resulting in no net difference in total weight loss compared to placebo.

Expect to gain 1-2 pounds in the first week of Growth Hormone therapy due to water retention. This is normal and temporary. Do not stop treatment because of this initial weight gain; it will resolve after you stop the injections.

SIRT1 levels in the brain decline with age, leading to cognitive impairment and metabolic dysfunction, while maintaining or increasing SIRT1 activity preserves synaptic plasticity and memory.

Maintaining brain health involves supporting SIRT1 activity, which declines with age. This supports the importance of lifestyle factors (like exercise and caloric restriction) that are known to upregulate SIRT1, potentially preserving memory and synaptic plasticity.

SIRT1 activation in the hypothalamus regulates energy metabolism and circadian rhythms, influencing susceptibility to diet-induced obesity and metabolic disorders.

Diet and exercise influence brain SIRT1 levels, which in turn regulate hunger and energy expenditure. This suggests that lifestyle interventions work partly by modulating central brain mechanisms, not just peripheral calorie burning.

Hepatocyte-specific deletion of MyD88 causes glucose intolerance, hepatic insulin resistance, and inflammation independently of body weight or fat mass gain.

This research highlights that liver-specific immune signaling (MyD88) is crucial for maintaining glucose and lipid balance. While you cannot change your genetics, understanding that liver health is distinct from body weight is key. High-fat diets can unmask or worsen underlying liver metabolic vulnerabilities, even in lean individuals. Focus on liver-supportive lifestyle choices (balanced diet, exercise) to mitigate genetic risks.

Hepatocyte MyD88 regulates bile acid synthesis and profile, which in turn influences gut microbiota composition and host glucose/lipid metabolism.

Your liver produces bile acids that act as hormones, influencing your gut bacteria and how you process sugar and fat. Disruptions in liver signaling (like inflammation) can alter these bile acids, potentially worsening metabolic health. A diet low in excessive fats may help maintain healthier bile acid profiles.

Pharmacologic inhibition of the mTORC1 pathway using rapamycin extends lifespan across multiple species, though its use in humans is limited by side effects like immunosuppression and metabolic dysfunction.

While rapamycin extends lifespan in animals, its side effects make it a poor choice for healthy humans. Instead, focus on lifestyle factors like caloric restriction or exercise, which naturally modulate the mTOR pathway without the severe risks of pharmaceutical inhibition.

Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to aging and age-related diseases by promoting chronic inflammation and tissue dysfunction.

Senescent cells accumulate with age and contribute to inflammation and tissue dysfunction. Emerging therapies aim to clear these cells (senolytics) to improve healthspan.

Cardiometabolic Syndrome (CMS) is an independent predictor of cardiovascular mortality and morbidity in older adults, with risk increasing as the number of CMS components increases.

Regularly check all components of Cardiometabolic Syndrome (blood pressure, blood sugar, lipids, waist circumference). Managing all of them together is more effective for preventing heart disease and stroke than treating just one.

Women with PCOS have an increased proportion of atherogenic small dense LDL particles and elevated Lipoprotein(a), which are independent risk factors for cardiovascular disease.

Request a complete lipid panel that includes Lipoprotein(a) and ApoB/ApoA-I, not just standard LDL-C. Even if your LDL is normal, elevated Lp(a) and small dense LDL particles common in PCOS increase heart disease risk. Statins may be necessary to address these specific abnormalities.

Moderate alcohol consumption (one to two drinks per day) is associated with a 30-40% lower risk of type 2 diabetes compared to abstinence.

If you already drink alcohol moderately (1-2 drinks/day), this habit is associated with a significantly lower risk of type 2 diabetes compared to not drinking. Do not start drinking for health benefits if you are a non-drinker.

Implementing a small incremental increase in sugar-sweetened beverage (SSB) tax rates (e.g., 13% to 18%) results in only small price increases and small reductions in SSB purchases, which is unlikely to significantly reduce obesity or noncommunicable diseases.

If you are designing public health policy, know that small tax hikes (like 5%) have minimal impact on consumption. To drive significant behavior change, tax rates must be substantial enough to alter shelf prices meaningfully, or they must be part of a broader regulatory strategy.

Decreasing the tax rate on low-sugar or artificially sweetened beverages (L-SSBs) leads to a significant increase in their purchase volume, potentially offsetting the health benefits of reduced high-sugar beverage consumption.

When designing tax policies, lowering taxes on diet drinks can lead to a surge in their consumption. Policymakers must consider if this substitution aligns with broader health goals, as artificial sweeteners may have their own health implications.